Pulse Biosciences Begins Feasibility Study for Thyroid Cancer Treatment with nPulse Technology
Event summary
- First patient enrolled in feasibility study for nPulse™ Vybrance™ Percutaneous Electrode System to treat papillary thyroid microcarcinoma (PTM).
- Study involves 30 patients across two sites: Sarasota Memorial Health Care System and UT MD Anderson Cancer Center.
- nPulse technology previously received FDA 510(k) clearance for soft tissue ablation, now under IDE for thyroid cancer applications.
The big picture
Pulse Biosciences is exploring the potential of its nsPFA technology beyond soft tissue ablation, targeting malignant thyroid tumors. This feasibility study represents an early-stage but strategic pivot into oncology applications, leveraging the nonthermal mechanism of nPulse to offer a minimally invasive treatment option. The collaboration with leading cancer centers like UT MD Anderson underscores the clinical credibility of this approach.
What we're watching
- Clinical Efficacy
- How the feasibility study results will demonstrate the safety and effectiveness of nPulse technology in treating thyroid cancer.
- Regulatory Pathway
- Whether the IDE study will pave the way for broader FDA approvals for thyroid cancer applications.
- Market Adoption
- The pace at which nPulse technology could be adopted as a nonthermal alternative to surgery or surveillance for low-risk thyroid cancer patients.
Related topics